ROG - Oncolytics Biotech stock rises 11% on positive safety data from colorectal cancer therapy

Oncolytics Biotech (NASDAQ:ONCY) is trading ~11% higher premarket after it said no safety concerns were noted in the three-patient colorectal cancer group in phase 1/2 trial testing its drug, pelareorep in combination with Roche's (ROG) atezolizumab. The company said an independent Data Safety Monitoring Board reviewing the drug also recommended that the study proceed as planned. The early-to-mid stage study will evaluate the safety and efficacy of the company's drug in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers.  The study, which is being managed by academic cooperative medical oncology group AIO, is being conducted in 14 clinical trial sites across Germany.  In early February, the safety board had cleared its combination therapy for pancreatic cancer group. The trial's anal cancer group does not include safety run-ins and are proceeding as planned, the company said.

For further details see:

Oncolytics Biotech stock rises 11% on positive safety data from colorectal cancer therapy